Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
King International InvestmentHKSE:00928 -4.85% EV-to-FCF is -13.68 as of Aug. 09, 2026. The stock has 5 warning signs investors should review. Among 101 Medical Diagnostics & Research companies, King International Investment ranks worse than 990098.02% on this metric.
The historical rank and industry rank for King International Investment's EV-to-FCF or its related term are showing as below:
HKSE:00928'
s EV-to-FCF Range Over the Past 10 Years
Min: -695.99 Med: -2.48 Max: 1.57
Current: -13.68
During the past 13 years, the highest EV-to-FCF of King International Investment was 1.57. The lowest was -695.99. And the median was -2.48.
HKSE:00928's EV-to-FCF is ranked worse than 100% of 101
companies
in the Medical Diagnostics & Research industry
Industry Median: 26.68
vs HKSE:00928: -13.68
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
King International Investment (HKSE:00928) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
King International Investment's PE Ratio (TTM) for today is calculated as:
King International Investment's share price for today is HK$0.098.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. King International Investment's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was HK$0.001.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
King International Investment EV-to-FCF Related Terms
King International Investment EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:00928 vs TMO, DHR, IDXX: EV-to-FCF Comparison
For the Diagnostics & Research subindustry, King International Investment's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
King International Investment EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, King International Investment's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where King International Investment's EV-to-FCF falls into.
King International Investment's current Enterprise Value is HK$182.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. King International Investment's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was HK$-13.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
King International Investment (HKSE:00928) has a EV-to-FCF of -13.68 as of Aug. 09, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on King International Investment and its competitors. According to the industry distribution chart, King International Investment ranks #999999 out of 101 companies in the Medical Diagnostics & Research industry.
Is King International Investment's EV-to-FCF too high?
King International Investment's current EV-to-FCF is -13.68. Based on the distribution chart, King International Investment ranks #999999 out of 101 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does King International Investment's EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, King International Investment ranks #999999 out of 101 companies for EV-to-FCF. This places King International Investment in the lower half of its industry. The industry median EV-to-FCF is 26.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 26.68, based on 101 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on King International Investment and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 26.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. King International Investment's current EV-to-FCF is -13.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is King International Investment stock overvalued right now?
Based on GuruFocus' analysis, King International Investment (HKSE:00928) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.04, compared to a current price of HK$0.10 — trading 145% above its estimated fair value. The current EV-to-FCF is -13.68. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For King International Investment (HKSE:00928), the current EV-to-FCF is -13.68 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
King International Investment Ltd is an investment holding company. Its operating segments include healthcare products and services, money lending, and liquor sales, with the majority of revenue generated from the liquor sales segment. The group provides genetic testing and develops domestic healthcare equipment services. Leveraging its strengths, the group integrates health data analysis software with healthcare equipment to offer new healthcare services and products. Geographically, it derives the majority of its revenue from the PRC.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00928 has been successfully added to your 
